Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fudan University
We administered 5-FU, lv and Oxaliplatin as adjuvant chemotherapy (3 weeks per cycle) to patients with Stage II or Stage III colorectal cancer. The study endpoints were disease-free survival, overall survival, and liver metastasis-free survival as evaluated by intent-to-treat analysis.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
age \< 75 years with histologically proven adenocarcinoma of the colon or rectum
no severe major organ dysfunction
WHO performance status of 0 or 1
Stage II (T3-4, N0, M0) or Stage III (T0-4, N1-2, M0) disease (according to the 1997 revision of the International Union Against Cancer TNM staging system)
You may not be if
age \>= 75
severe major organ dysfunction
WHO performance status of \>1
Stage I or Stage IV
Clareo Health | Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles
